ClinicalTrials.gg

Arthritis, Juvenile clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 366 studies for Arthritis, Juvenile across more than 10 countries. 101 are recruiting or about to start. 278 of them are mainly about Arthritis, Juvenile (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
182
Recruiting
68
Status unknown
38
Not yet recruiting
28
Terminated
21
Withdrawn
13

Phase

Phase 3
80
Phase 2
33
Phase 4
25
Phase 1
25
Early Phase 1
3

Where

United States
109
France
71
Italy
56
Canada
53
Germany
53
Spain
49

Who develops what

Add Arthritis, Juvenile to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 9 programs from 7 companies, 7 with this as their studies’ main aim; 4 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Novartis, R-Pharm and Alfasigma here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
tocilizumabRecent, limited
Evidence
  • NCT05609630 · AbbVie · Phase 3 · live · comparator · “Tocilizumab” · registered Nov 2022
  • NCT04088396 · Eli Lilly and Company · Phase 3 · live · comparator · “Tocilizumab” · registered Sep 2019
Hoffmann-La Roche89% of its industry studiesUS: Hoffmann-La Roche (FDA 2010) + 3 othersEU: Hoffmann-La Roche (EMA 2009) + 4 others11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
filgotinibApproved: EU 2020☆ Track2 live phase-3 studies: NCT07553182, NCT07554495Alfasigma S.p.A.
goflikicept☆ Track1 live phase-3 study: NCT07625384R-Pharm
deucravacitinibApproved: US 2022 · EU 2023☆ Track1 live phase-3 study: NCT06869551Bristol-Myers Squibb
Interleukin 1 Receptor Antagonist ProteinApproved: US 2001 · EU 2002☆ Track1 live phase-3 study: NCT05814159Swedish Orphan Biovitrum

The 4 in phase 3 with the nearest primary completion, of 9 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 22 Apr 2027 est.arumakimig · Novartis · Phase 2 main aimNCT07203001 A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease — primary endpoint: Number of participants with clinical response based on one set of response criteria · 30 enrolled
  • Jun 2027 est.filgotinib · Alfasigma S.p.A. · Phase 3 main aimNCT07554495 Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents — primary endpoint: Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation · 65 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Arthritis, Juvenile studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here JAK inhibitors 7 open · Tyrosine kinase inhibitors (TKIs) 7 open · Antimetabolites 3 open · NSAIDs 6 · COX-2 inhibitors 4

Coming up

17studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger. 64 (94%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 11 (16%) take healthy volunteers.

Recruiting studies that take each age, of 68
AgeWomenMen
1057 (84%)57 (84%)
1848 (71%)48 (71%)
3023 (34%)23 (34%)
4022 (32%)22 (32%)
5022 (32%)22 (32%)
6519 (28%)19 (28%)
7519 (28%)19 (28%)
8519 (28%)19 (28%)

Across all 366 studies, recruiting or not: 82% stop at 75 or younger and 81% at 65; 92% take children; 2% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Arthritis, Juvenile studies take

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 342 mo30–77 · 36 studies——
Interventional, no phase14 mo8–39 · 56 studies—13 mo8–35 · 53 studies
Observational81 mo26–186 · 42 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 366. Browse all 366 → or search them.